Should antitubercular therapy be discontinued now or should further investigations be performed to definitively exclude tuberculous meningitis in an 18‑year‑old female with one‑month history of headache and fever, normal MRI, and cerebrospinal fluid showing lymphocytic pleocytosis (16 cells/mm³), normal glucose (74 mg/dL) and mildly elevated protein (88 mg/dL) after five weeks of treatment?

Continue ATT and Perform Additional Diagnostic Testing

Do not stop antitubercular therapy (ATT) at this point; instead, pursue further diagnostic investigations while continuing treatment, as the CSF findings and clinical presentation do not definitively exclude tuberculous meningitis (TBM), and premature discontinuation risks catastrophic outcomes if TBM is present.

Rationale for Continuing Treatment

The CSF profile presented—lymphocytic pleocytosis (16 cells/mm³), normal glucose (74 mg/dL), and mildly elevated protein (88 mg/dL)—is atypical but not incompatible with TBM. While classic TBM typically shows more pronounced abnormalities (higher cell counts, lower glucose, significantly elevated protein), atypical presentations are well-documented 1. A recent case report specifically describes TBM initially presenting with low levels of pleocytosis and protein, emphasizing that early CSF findings can be misleading 1.

The one-month history of headache and fever in an 18-year-old female warrants high clinical suspicion, particularly given that:

• TBM is a medical emergency where treatment delay is strongly associated with death 2
• Negative or atypical initial findings should not exclude the diagnosis 3, 4
• CSF findings can evolve over time, with cellular composition and biochemical parameters changing during the disease course 5

Specific Additional Investigations to Pursue

Before considering stopping ATT, obtain:

Microbiological Testing

• Repeat lumbar puncture with large-volume CSF collection (≥6 mL): Diagnostic yield increases substantially with volume and repeated sampling 2
• CSF acid-fast bacilli (AFB) smear and mycobacterial culture: Though sensitivity is low (30-40%), specificity is 100% 4
• GeneXpert MTB/RIF PCR on CSF: Highly specific but sensitivity is only 50-60%; negative results do not exclude TBM 3, 4
• CSF adenosine deaminase (ADA): Elevated levels support TBM diagnosis 5

Extra-neural Site Sampling

• Chest X-ray/CT: Look for pulmonary TB
• Gastric aspirates, sputum cultures if pulmonary findings present
• Lymph node biopsy if lymphadenopathy present
• HIV testing: Essential as it affects management and broadens differential 2

Advanced CSF Analysis

• Repeat CSF examination after 1-2 weeks: Look for evolution in cell count, protein, glucose, and presence of cobweb coagulum 5
• CSF lactate levels: May help differentiate bacterial from viral causes

Imaging Reassessment

• Repeat MRI with contrast: Look specifically for basal meningeal enhancement, tuberculomas, hydrocephalus, or vasculitic changes that may develop over time 6

Treatment Duration Considerations

If TBM is confirmed or remains the working diagnosis:

• Total treatment duration should be 12 months (not 6 months as with pulmonary TB) 7, 2
• Initial 4-drug regimen: Isoniazid, rifampin, pyrazinamide, plus ethambutol (or streptomycin) for 2 months 7, 2
• Continuation phase: Isoniazid and rifampin for 10 additional months 2
• Adjunctive corticosteroids: Dexamethasone or prednisolone tapered over 6-8 weeks is strongly recommended for TBM 7, 2

Critical Pitfalls to Avoid

1. Stopping treatment based solely on atypical CSF findings: This is the most dangerous error, as TBM can present with minimal CSF abnormalities early in disease 1

2. Relying on single negative molecular tests: GeneXpert sensitivity is suboptimal; negative results cannot rule out TBM 3, 4

3. Failing to repeat lumbar puncture: Serial CSF analysis provides dynamic assessment of disease evolution and treatment response 5

4. Premature discontinuation before 5 weeks: You are only at the midpoint of the initial intensive phase; stopping now would be inappropriate even if diagnosis were certain

Alternative Diagnoses to Consider

While pursuing TBM workup, also investigate:

• Viral meningitis (though typically resolves within 2-4 weeks)
• Fungal meningitis (Cryptococcus, especially if immunocompromised)
• Autoimmune/inflammatory conditions (though less likely with fever)
• Partially treated bacterial meningitis

The risk-benefit analysis strongly favors continuing ATT while completing the diagnostic evaluation, as the morbidity and mortality of untreated TBM far exceed the risks of continuing empirical therapy for several more weeks while awaiting definitive results 2, 8.